EntreMed, Inc. has announced the execution of an agreement granting Oxford BioMedica plc exclusive worldwide rights to develop the localized delivery of two gene targets from EntreMed as a possible treatment for the loss of vision. Neil Campbell, EntreMed President and Chief Operating Officer, commented, “Given Oxford BioMedica’s gene therapy expertise, we are pleased that Read more about Licensing Deal For EntreMed And Oxford BioMedica[…]